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Abstract
Background: Chronic kidney disease (CKD) is common and is associated with excess mortality and morbidity.
Better management could slow progression of disease, prevent metabolic complications, and reduce cardiovascular
outcomes. Low patient awareness of CKD and ineffective patient-provider communication can impede such efforts.
We developed provider and patient-directed interventions that harness health information technology to enhance
provider recognition of CKD and delivery of guideline concordant care and augment patient understanding and
engagement in CKD care.
Methods/design: We report the design and protocol of the Kidney Awareness Registry and Education (KARE)
Study, a 2x2 factorial randomized controlled trial that examines the impact of a multi-level intervention on health
outcomes among low-income English, Spanish and Cantonese-speaking patients with CKD in a safety net system.
The intervention includes: (1) implementation of a primary care electronic CKD registry that notifies practice
teams of patients’ CKD status and employs a patient profile and quarterly feedback to encourage provision of
guideline-concordant care at point-of-care and via outreach; and (2) a language-concordant, culturally-sensitive
self-management support program that consists of automated telephone modules, provision of low-literacy written
patient-educational materials and telephone health coaching. The primary outcomes of the trial are changes in systolic
blood pressure (BP) and the proportion of patients with BP control (≤140/90 mmHg) after one year. Secondary
outcomes include patient understanding of CKD, participation in healthy behaviors, and practice team delivery of
guideline-concordant CKD care.
Discussion: Results from the KARE study will provide data on the feasibility, effectiveness, and acceptability of
technology-based interventions that support primary care efforts at improving health outcomes among vulnerable
patients with CKD.
Trial registration: ClinicalTrials.gov, number: NCT01530958
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Background
Chronic kidney disease (CKD) is common, with an esti-
mated prevalence of 11.5 % among the U.S. adult popu-
lation [1], causes excess mortality [2], and is associated
with significant socio-demographic disparities [3, 4]. Ra-
cial/ethnic minorities and the poor, often treated in
safety-net health systems, are more likely to have CKD
at an earlier age [5–7]. Although randomized controlled
trials have demonstrated that measures such as blood
pressure control [8], reduction of proteinuria with angio-
tensin converting enzyme inhibitors (ACEi) or angioten-
sinogen receptor blockers (ARB) [9–11], and glycemic
control among persons with diabetes [12, 13], can delay
CKD decline and decrease CKD-associated morbidity
and mortality [14], many individuals with CKD are not
benefiting from these scientific advances. Lack of trans-
lation may be due to low levels of CKD awareness
among providers and patients [15–17]; low self-efficacy
among primary care providers for delivery of CKD care
[18], particularly in an inefficient health care system with
overburdened providers that deliver chronic disease care;
and poor patient empowerment to participate in healthy
lifestyles, adhere to medication regimens, and avoid
nephrotoxic insults [19, 20].
The Chronic Care Model posits that an informed
patient and prepared practice team have productive
interactions that lead to improved outcomes [21]. It pro-
vides a framework for the delivery of high-quality
chronic disease care and can be integrated into the
Patient Centered Medical Home [22]. Implementation of
single elements of the Chronic Care Model (e.g., health
care organization, community resources, patient self-
management support, delivery system re-design, decision
support) can improve processes of care, such as de-
creased hospitalizations among patients with congestive
heart failure [23]. Interventions that have enhanced pa-
tient outcomes have incorporated several elements of
the Chronic Care Model [24]. For example, data from
the North Carolina Improving Performance in Practice
program, a state-wide quality improvement program
aimed at improving health outcomes among patients
with diabetes, demonstrated a positive graded associ-
ation between improved cholesterol levels among
patients with diabetes and the extent to which clinical
practices implemented and used the following compo-
nents of the multi-level intervention: diabetes and lipid
registry, list of standardized items that are addressed
with every diabetic patient at every visit, comprehensive
care protocols for diabetes management and patient self-
management support systems [25].
Sustainable multi-level interventions that enhance
CKD management in primary care settings are rare, and
none have been studied in U.S. safety-net delivery systems,
where vulnerable populations (e.g., the poor, minorities,
limited health literacy/English proficiency) bear a dispro-
portionate burden of disease [5, 26] and experience large
translational gaps between research and practice [27]. We
describe the design and protocol of the Kidney Awareness
Registry and Education (KARE) study, which assesses the
effectiveness and feasibility of a multi-level intervention to
improve blood pressure control among low-income
patients with CKD. The intervention targets primary care
practice teams and patients using multiple elements of the
Chronic Care Model, including delivery system redesign,
decision support, patient self-management support,
organizational change and information systems. It also
harnesses the core elements of a Patient Centered Medical
Home, including robust data infrastructure, team-based
delivery of chronic disease care and provider and patient
education. The KARE intervention consists of: (1) an elec-
tronic CKD registry that provides point-of-care decision
support to clinicians regarding CKD management; (2)
outside-of care summaries of CKD relevant clinical data
to optimize delivery of guideline-concordant CKD care by
practice teams; and (3) a comprehensive patient self-
management support program, entitled CKD-ATSM
(automated telephone self-management), that includes
low-literacy educational materials; proactive, automated
telephone self-management support; and live telephone
health coaching (Fig. 1).
Methods/design
Study design
KARE is a non-blinded 2x2 factorial randomized con-
trolled trial with two levels of randomization. Primary
care providers are randomized to one of two arms: ac-
cess to an electronic CKD registry or usual care. Patients
are subsequently randomized to one of two arms: CKD
self-management program (CKD-ATSM) or usual care.
This study design, with 4 study arms, allows assessment
of the individual and additive impact of both interven-
tions (Fig. 2). Approval to conduct this study was
granted by the Committee of Human Research at the
University of California, San Francisco.
Study population and setting
Patients with CKD and their providers are recruited
from primary care clinics in the San Francisco Health
Network, the integrated public health care delivery system
serving San Francisco’s uninsured and publicly insured
residents. The study team collaborates with the staff at
each clinic to implement and monitor the study.
Eligibility criteria
Providers
All primary care providers, including attending physi-
cians, family practice and internal medicine trainees,
nurse practitioners and physician assistants who provide
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Fig. 1 KARE incorporates components of the Chronic Care Model and integrates with a patient-centered medical home to enhance
health outcomes
Fig. 2 KARE 2x2 factorial clinical randomized trial design
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longitudinal primary care to patients, are eligible for
this study. Providers who solely provide specialty care,
for example HIV services, psychiatric care or urgent
care, are excluded from the study.
Patients
Eligible patients include adults (>18 years) with CKD,
defined by an eGFR 15–60 ml/min/1.73 m2 or presence
of at least two 1+ dipstick albuminuria separated by at
least 90 days. Estimated GFR is calculated using the
Modified Diet in Renal Disease study equation [28], as
this is automatically reported by the electronic medical
record (EMR). Patients must have had contact with their
primary health care team at least once within the past
2 years and speak English, Spanish or Cantonese. Kidney
transplant recipients, pregnant women, and individuals
on dialysis are excluded from this study. Other exclusion
criteria include those that impede meaningful communi-
cation between providers and patients or limit the use-
fulness of a CKD self-management support program:
prevalent dementia, impaired cognition or severe mental
illness; expected life expectancy <6 months; self-reported
hearing impairment or severe visual impairment pre-
venting use of a touchtone telephone keypad.
Identification and recruitment
Providers
Clinical leadership of primary care clinics in the San
Francisco Health Network are approached to participate
in this study. All providers from participating clinics are
recruited to take part in KARE.
Patients
The San Francisco Health Network’s electronic patient
registry is searched to identify eligible study participants.
Primary care providers are sent a letter outlining the
study objectives with a list of their potentially eligible
patients. Providers are asked to identify patients who
should be excluded from the study based on the afore-
mentioned exclusion criteria. After receiving provider
approval, eligible patients are contacted via telephone to
inform them of the study, ensure eligibility, and schedule
an enrollment appointment. Voicemails are left for
patients who do not respond. For patients who do not
respond to 3 phone calls or messages, an attempt is
made to call the emergency contact individual listed in
the EMR. Successful contact results in an update of the
eligible patient’s contact information in the EMR and
three additional attempts to contact the patient.
Enrollment and randomization
Providers
Consistent with the patient-centered medical home, cli-
nicians in participating primary care clinics are assigned
to practice teams responsible for distinct panels of pa-
tients. Each team consists of several physicians, nurses,
nurse practitioners, medical assistants and behaviorists.
Within each clinic, patient demographics across practice
teams are similar with respect to race/ethnicity, gender,
age and language distribution. To minimize contamin-
ation among clinicians, practice teams, rather than pri-
mary care providers, are randomized to receive the CKD
registry or to receive usual care.
Patients
Prior to enrollment, using blind and secure allocation by
computer, the study team randomly assigns participants
to one study arm using a random number generator:
CKD-ATSM or usual care. Randomization is blocked
and stratified within primary care provider to increase
the comparability of treatment groups and to ensure
equal allocation by provider. Results are placed in a
sealed randomization envelope by a study coordinator.
At the study enrollment appointment, the study team
obtains written informed consent and collects baseline
study measures. At the completion of this baseline visit,
patients learn about their randomization assignment by
opening the randomization envelope. Subjects random-
ized to the intervention arm are provided printed
instructions about how to participate in the telephone
self-management program and are guided through the
process of creating a personalized log-in code for the
automated telephone modules. Patients are also given a
business card from his/her assigned health coach and a
schedule of study events. If randomized to usual care,
patients only receive a schedule of study events. All
patient participants receive a $50 gift card to a local
supermarket for their participation in the study.
Interventions
Provider intervention
The CKD registry was designed to alert clinicians of a
patient’s CKD-relevant information and was created
with input from San Francisco Health Network clin-
ical leadership and quality improvement champions
[29]. This registry, which uses i2iTracks software
(http://www.i2isys.com/p/i2itracks), searches the EMR
and identifies individuals with CKD based on eGFR and
albuminuria, either by dipstick or urinary albumin:creati-
nine ratio. A printed patient profile provides the primary
care practice team with point-of-care data on CKD status,
recent blood pressure readings, prescription of pertinent
medications (aspirin, ACEi, ARB, statin), recent quantifi-
cation of albuminuria and recent low-density lipoprotein
values, as well as non-CKD specific data that practice
teams in the control group receive: immunization status
and data pertinent to age appropriate cancer screening.
Practice team medical assistants use the patient profile
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while obtaining vital signs during the clinic visit to identify
all patients who are not up to date with their age appro-
priate cancer screening and patients with CKD who need
albuminuria quantification and immunizations. The regis-
try also encourages them to notify primary care providers
about lapses in guideline-concordant CKD care delivery
by highlighting blood pressure readings that are above
140/90 mmHg and noting when patients are not on an
ACEi or ARB. Written decision support on the pa-
tient profile also reminds primary care providers to
avoid prescribing non-steroidal anti-inflammatory medica-
tions for patients with CKD and to prescribe statin medi-
cations when appropriate.
Quarterly written feedback to practice teams focuses
on three important groups of patients with CKD: those
with uncontrolled BP, those not prescribed an ACEi or
ARB, and those with persistent macroalbuminuria [14].
Individual PCPs also receive printed sheets identifying
their patients who fall in the above categories.
Provider usual care
Usual care consists of a patient profile that only includes
data pertinent to age-appropriate cancer screening. Prac-
tice team medical assistants use the patient profile while
obtaining vital signs to identify patients who are not up
to date with respect to colon cancer, breast cancer and/
or cervical cancer screening.
Patient intervention
The comprehensive CKD self-management support pro-
gram consists of three distinct elements that are based
on the Social Cognitive Theory constructs of behavioral
capability, self-efficacy, expectations and reinforcement
[30, 31]: (1) patient educational materials about CKD;
(2) automated telephone self-management (CKD-
ATSM); and (3) live telephone-based health coaching.
CKD-ATSM was developed with key input from local
clinicians to meet the mutli-lingual, low-literacy and
diverse cultural needs of the San Francisco safety-net
patient population and has been successfully employed
in diabetes care [32]. The program consists of 27 different
modules that cover topics pertinent to kidney health: ba-
sics of kidney disease and its association with hyperten-
sion; importance of participation in healthy behaviors
(diet, physical activity, smoking cessation, stress reduc-
tion); avoidance of non-steroidal anti-inflammatory medi-
cations; participation and preparation for clinic visits,
complementary medication use; medication adherence;
and glycemic control. Offered in English, Spanish, and
Cantonese, each phone call has educational messages
about 1–2 topics (i.e., nephrotoxic medications), followed
by culturally tailored vignettes that highlight self-
management behaviors that encourage patients to over-
come barriers to engage in their own health and decrease
risk of morbidity (i.e., use of Acetaminophen instead of
NSAIDS to minimize risk of acute kidney injury). Embed-
ded within these automated phone calls are simple queries
that allow the study team to capture data and the health
coach to respond to out of range values. The study health
coaches receive these data on a weekly basis, allowing
them to generate live phone calls to those patients who
provide alarming or “out or range” data (i.e., responding
“3 or greater” to the question “In the last 7 days, how
many days did you miss taking a medication?”). During
the live phone calls, health coaches can provide add-
itional education and encourage behavior change
through motivational interviewing and action plan-
ning. Phone interactions are documented in the EMR,
providing seamless integration into medical care
(Fig. 3).
The bilingual health coaches employed for this study
do not have a medical background. To prepare for the
KARE study, they attend 18 h of training led by the
UCSF Center for Excellence in Primary Care (http://
cepc.ucsf.edu/health-coaching). Training is conducted
in English, using a curriculum developed by the trainers
and study team. Curriculum modules include: working
collaboratively with patients; basics of CKD; knowledge of
common cardiovascular medications; recognizing “red
flags” such as symptoms of depression and not taking any
medications; difficulty navigating the clinic; and accessing
community resources. Furthermore, coaches are trained
to interact with patients using active listening, provide
social and emotional support, assist with lifestyle changes
and facilitate medication understanding and adherence.
Language-concordant, low-literacy written patient
educational materials (PEMs) are given to study partici-
pants at baseline and throughout the study period. PEMs
were selected after a thorough review of available CKD
educational materials [33]. Health coaches refer to these
PEMs during their live telephone calls to reinforce con-
cepts and encourage further engagement.
Patient usual care
Subjects randomized to not receive CKD-ATSM con-
tinue to receive medical care at their primary care clinic.
They are eligible to receive any of the clinic’s usual
resources, including interactions with non-physician
health care providers, such as nurses, pharmacists, and
educators. These resources are also available to study
participants randomized to receive CKD-ATSM.
Data collection, follow-up and outcomes
Data collection
In addition to clinical and behavioral outcomes, baseline
data are collected to describe the characteristics of study
participants (providers and patients) and compare these
characteristics between intervention groups assigned by
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randomization. These data include: self-reported pro-
vider demographic data (age, gender, years of experience,
specialty, preferred language), provider perception of
practice team cohesiveness, self-reported patient socio-
demographic data (age, gender, race/ethnicity, social
support, education, income, health literacy, zip code,
insurance status), co-morbid conditions (diabetes, hyper-
tension, cardiovascular disease), food insecurity, and
health literacy (Table 1).
Clinical outcomes
The primary outcomes are changes in systolic BP and
proportion of patients with BP control (<140/90 mmHg)
after one year. The study team will measure BP using an
Omron digital blood pressure monitor model HEM-
907X during baseline and 12-month study visits. Per
study protocol and American Heart Association guide-
lines, study personnel will obtain 3 BP measures in the
right arm after the participant has been sitting quietly
for 5 min [34]. An average of the 3 measures is recorded.
Secondary clinical outcomes include: changes in urine
albuminuria and weight obtained during by the study
team, as well changes in eGFR, laboratory measures of
metabolic bone disease (serum calcium, phosphorous,
25-OH Vitamin D and parathyroid hormone) and glyco-
sylated hemoglobin among participants with diabetes, all
ascertained through the EMR.
Behavioral outcomes
Provider and patient behavioral outcomes will inform
mechanisms by which the interventions are or are
not successful. We will examine changes in provider
awareness/identification of CKD, self-efficacy of de-
livering CKD guideline-concordant care, comfort in
provider communication with patients about CKD,
prescription of ACEi or ARB, quantification of albu-
minuria and nephrology referral. These behavioral
data will be ascertained at baseline and at 12 months,
using validated instruments when available [35, 36]
(Table 1). We will also assess changes in patient
awareness of CKD, self-efficacy toward chronic dis-
ease self-management, participation in healthy be-
haviors, medication adherence, and comfort in
communicating with providers [37–40] (Table 1).
Process measures
Many interventions with efficacy ultimately fail because
they are not sustained in clinical practice. KARE inter-
ventions were designed for integration into clinical care.
We will use the Reach, Effectiveness, Adoption, Imple-
mentation, and Maintenance (RE-AIM) framework of
program evaluation and implementation to evaluate
process and feasibility measures [41]. To examine adop-
tion of KARE interventions, we will survey clinicians
and primary care clinic staff about integration with clinic
Fig. 3 CKD-ATSM blends health technology with personalized education and counseling
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workflow. We will also assess implementation or fidelity
of the self-management program with data from the
ATSM information technology platform and audio
recordings of health coach conversations. To assess
maintenance or sustainability of KARE interventions,
we will ask patients about overall satisfaction, com-
prehension of self-management support, and burden
of the intervention during language-concordant focus
groups. Provider and practice team satisfaction with
the program will be ascertained via survey and focus
groups respectively. The resources associated with
starting and maintaining each successful intervention
will be calculated including personnel time, equipment,
and information technology (Table 2).
Sample size considerations
Sample size and power calculations were performed for
the main outcome of interest – change in systolic BP (sBP)
after 1 year due to each intervention individually – using
effects sizes and standard deviations from multiple pub-
lished trials of interventions to improve BP control. Base-
line data among patients with CKD in the San Francisco
Health Network demonstrate an average sBP of 151 mmHg
(range: 140–160) across primary care providers, with an
intra-class coefficient = 0.0008. Thus, we used simple t-test
calculations to determine power analysis. Using a two-
tailed alpha of 0.05 and beta of 0.8, we need to enroll 200
patients to each intervention (CKD-ATSM vs. usual care
and CKD-registry vs. usual care) to detect a 6-point change
Table 1 Kidney Awareness Registry and Education (KARE) study variables and outcomes
KARE Study data collection Method of ascertainment Baseline Mid-point Study end
Primary care providers
Demographic data
Age, gender, years of experience, language Survey +
Behavioral data
Awareness/ability to identify CKD questionnaire [35] + +
Self-efficacy towards CKD management questionnaire + +





Prescription of ACEi or ARB, albuminuria
quantification, nephrology referral
Medical record + +
Patients
Demographic data
Age, gender, race/ethnicity, social support,
income, education, zip code, preferred
language, insurance status
Survey +
Food insecurity, health literacy Screening questions +
Clinical data
BP, Height, Weight, UACR, Measured by study team + +
eGFR, metabolic bone disease parameters,
glycosylated hemoglobin
Medical record + +
Co-morbid conditions Medical record + +
Referrals, emergency department visits,
hospitalizations
Medical record + +
Current medications Medical record and study team + + +
Quality of life, functional status SF-12 instrument [37] + +
Behavioral data
CKD awareness Survey + + +
Participation in healthy behaviors BRFSS questionnaire [40] + + +
Self-efficacy for self-management Stanford self-efficacy tool [39] + + +
Medication Adherence Morisky Medication Adherence
Scale [38]
+ + +
Communication with providers Lorig Communication tool [39] + + +
CKD chronic kidney disease, ACEi angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, UACR urine albumin:creaitnine ratio, eGFR estimated
glomerular filtration rate, QOL quality of life, BRFSS Behavioral Risk Factor Surveillance System
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in systolic BP. This is similar to that achieved by previous
team-based intervention trials [42]. Using an interaction
analysis, we will also be able to detect a 12-point difference
in systolic BP between the arm that receives no interven-
tion and the arm that receives both interventions. To ac-
count for a 10 % loss to follow-up, we will need to enroll
220 patients to each intervention, or 110 patients to each
arm of the 2x2 factorial design.
Data analysis
Evaluation of the individual effectiveness of each inter-
vention, as well as their additive impact, will be per-
formed with intention to treat analyses using generalized
estimating equations adjusting for patient age, clinic and
preferred language, with robust standard errors to account
for clustering by provider and repeated patient measures
within provider. If significant differences in baseline
characteristics (i.e., age, diabetes status) are found among
subjects in each study arm, analyses will be adjusted for
these differences using multi-variable linear regression.
Additional analyses will look for evidence of effect modifi-
cation by primary language and CKD severity.
Discussion
Despite scientific advances that can delay CKD decline
and decrease CKD-associated morbidity and mortality,
and incorporation of these advances into national [43]
and international [44] guidelines, delivery of guideline
concordant CKD care remains elusive for many kidney
disease patients [45, 46]. This is particularly true among
patients who receive care in safety-net settings, where
translation of evidence into practice is often impeded by
low patient awareness of CKD, poor patient engagement
in care, competing clinical demands, and an inefficient
health care delivery system [47].
Patient self-management support is an important com-
ponent of chronic care management, yet many primary
care practices do not consistently provide this support
due to limitations of training, time, and resources. Lin-
guistically and culturally concordant health coaches are
an untapped resource to provide this support, as demon-
strated by a recent study that demonstrated improved
BP, glycemic and lipid control among low-income,
hypertensive, diabetic or hyperlipidemic patients work-
ing with medical assistant health coaches [48]. The
KARE study tests the impact of a comprehensive CKD
self-management support program that occurs outside
of the primary care encounter and employs accessible
technology and lay health coaches to enhance patient
awareness of CKD and engagement with care.
Supporting providers in their delivery of CKD-care is
key to maximizing the clinical benefits of patient health
coaching. The KARE study will test the effectiveness of a
primary care electronic CKD registry with elements of
point-of-care decision support and out-of-care population
health, to empower non-physician practice team members
to participate in the delivery of guideline concordant care.
We hypothesize that patients who receive ATSM and
health coaching, and whose practice teams are random-
ized to the registry, will show significant improvement
Table 2 Process outcomes to be studied in the Kidney Awareness Registry and Education (KARE) study
RE-AIM dimension Outcome Method of Assessment
Adoption 1. Are providers and staff satisfied with integration
into clinic work flow?
Survey
Implementation 1. Are automated telephone recordings delivered
as intended?
Data from ATSM information technology platform;
comparison of audio recordings of health coach
conversations vs. CKD-ATSM manual
2. Is the health coaching intervention delivered
as intended?
3. Is health coaching similar across all health
coaches, despite language differences?
Maintenance (patient) 1. Are there any difficulties in participating?
Unanticipated issues?
Focus groups and questionnaire at study conclusion
2. Are there any unintended consequences of
receiving self-management support?
Maintenance (Provider) 1. Do providers read the electronic notes entered
by the health coach?
Focus groups and questionnaire at study conclusion
2. Do medical assistants use the patient profile routinely?
3. Are there unanticipated consequences of the CKD
registry on delivery of non-CKD chronic disease care?
Maintenance 1. Time needed by practice teams to engage with
CKD-registry and perform outreach
Health Coach logs, study reports
2. Costs (supplies, time spent by health coaches and
their salaries) for delivery of CKD-ATSM
CKD chronic kidney disease, ATSM automated telephone self-management
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in systolic BP, reduction in albuminuria, and achieve
higher self-efficacy for CKD self-management. If KARE
interventions are indeed effective at improving health
outcomes among safety-net patients with CKD, the iden-
tification of feasible and sustainable characteristics will
facilitate their dissemination to other delivery systems
across the United States, advancing the goal of healthy
equity for people with CKD.
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